Abdominal ImagingNCT05261633
Diffusion MRI of the Abdomen
An observational study of Abdominal Imaging, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
The purpose of this research is to see if a new magnetic resonance imaging (MRI) method will be able to improve the images taken of the abdomen. This new method includes some changes to help avoid movements that may disrupt the images like breathing, heartbeats and other involuntary motion that occurs in the abdomen. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Abdominal Imaging
- What is being tested?
- Diffusion Weighted Magnetic Resonance Imaging
- Type of treatment
- Injection or infusion, Medical device
- How many people
- 17 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Nov 2023to 30 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Healthy volunteers and people with known liver metastases that are 18 years or older.
Who may be able to join
- 18 years of age or older
- 18 years of age or older
- Patients with at least one of the following:
- Radiologically visible solid tumor liver metastasis, with at least one metastatic liver lesion must be a minimum of 8 mm in longest diameter
- Patients presenting for liver lesion biopsy
Who cannot join
- Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
- Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
- Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
- Patients with known contraindication to GBCA such as severe kidney disease or previously documented GFR < 30 ml/min/1.73 m2
- Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:
- The subject has their own prescription for the medication.
Show all 11Show fewer
- The informed consent process is conducted prior to the self-administration of this medication
- They come to the research visit with a driver
- Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
- Stent in bile ducts
- Partial hepatectomy
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53792
About this study
Official title: Diffusion Magnetic Resonance Imaging (MRI) of the Abdomen
The purpose of this research is to see if a new magnetic resonance imaging (MRI) method will be able to improve the images taken of the abdomen. This new method includes some changes to help avoid movements that may disrupt the images like breathing, heartbeats and other involuntary motion that occurs in the abdomen. This study will these methods in healthy volunteers and validate them in patients with known liver metastases in a single contrast-enhanced MRI visit.
Read the detailed description
This study will develop and validate novel DW-MRI methods with unprecedented robustness to motion, favorable image quality, and quantitative precision for abdominal imaging. Upon successful completion, these methods will have broad applications, including the assessment of cancer, fibrosis and other disease processes in various abdominal organs such as the liver, pancreas, kidneys, bowel and beyond.
The primary objective is to demonstrate precise quantitative diffusion parameter mapping that is achieved by the novel, motion-robust, low-distortion DW-MRI methods in a representative and clinically relevant application, for the assessment of liver metastatic disease. Specifically, the investigators will:
- Compare the repeatability of DW-MRI methods by calculating the squared difference between each pair of repeated ADC measurements in lesions and healthy tissue, and will model this value including the DW-MRI method as a covariate using Generalized Estimating Equations (GEE).
Secondary objectives include optimization of the methods in healthy volunteers, assessment of image quality and distortions, as well gathering preliminary data for assessment of sensitivity and specificity for detection of lesions:
- Optimization in healthy volunteers
- (Aim 1) Optimized bh, M1 and M2 parameters by minimization of the mean squared error and bias of ADC quantification across the liver
- (Aim 2) Optimized motion-corrected averaging via image quality assessment by three radiologists using a Likert scale.
- SNR (signal-to-noise ratio) will be evaluated for each DW-MRI dataset, using an expectation-maximization method, accounting for parallel imaging, spatially varying noise, and magnitude operation.
- To assess image distortions in DW-MRI, the cross-correlation coefficient (CCC) will be used to assess alignment between each of the DW-MRI datasets and the reference T2-weighted acquisition.
- Each DW-MRI reconstruction will be evaluated by three radiologists using a Likert scale between 0 (worst/non-diagnostic) and 4 (best) for several criteria: motion artifacts, spatial resolution, distortions, apparent SNR, and overall image quality. The post-contrast images will serve as a guide to assess for artifacts by demonstrating the liver and the lesions.
- Per-lesion sensitivity, specificity, and accuracy will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.
- Intra-reader variability will be assessed by each reader will repeating ADC measurements after two months.
- Inter-reader variability will be assessed in ADC measurements by comparing matching lesions, based on the recorded lesion location across readers.
Specific Aims Aim 1: Optimize a reliable, motion-robust DW-MRI of the abdomen in healthy volunteers.
Aim 2: Optimize, in healthy volunteers, a high-resolution, low-distortion, motion-robust DW-MRI of the abdomen through the synergistic combination of motion-robust DW-MRI with state-of-the-art low-distortion techniques.
Aim 3: Demonstrate excellent image quality and precise quantitative diffusion parameter mapping using the novel DW-MRI methods in a representative and clinically relevant application for the assessment of liver metastases, by evaluating in patients:
3a. Quantitative and subjective image quality metrics. 3b. Precision (test-retest repeatability) of ADC measurements in the liver (including healthy parenchyma and lesions) by novel vs. standard DW-MRI methods.
- Conditions
- Abdominal Imaging
- Being tested
- Diffusion Weighted Magnetic Resonance Imaging
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diffusion Weighted Magnetic Resonance ImagingDevice
Also called DW-MRI
Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
| Study group | Role | What they receive |
|---|---|---|
| Healthy Volunteers | Not described Receives: Device: Diffusion Weighted Magnetic Resonance Imaging | |
| Known Liver Metastases | Not described Receives: Device: Diffusion Weighted Magnetic Resonance Imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Squared difference between each pair of repeated ADC measurements
Compare the repeatability of DW-MRI methods by calculating the squared difference between each pair of repeated apparent diffusion coefficient (ADC) measurements in lesions and healthy tissue, and will model this value including the DW-MRI method as a covariate using Generalized Estimating Equations (GEE).
Measured: up to 1.5 hours
Secondary outcomes (10)
Mean Squared Error of ADC in images from Healthy Volunteers
Optimized bh, M1 and M2 parameters in healthy volunteers by minimization of the mean squared error and bias of ADC quantification across the liver.
Measured: up to 1.5 hours
Image Quality Score in images from Healthy Volunteers
Optimized motion-corrected averaging in healthy volunteers via image quality assessment by three radiologists using a Likert scale, ranging between 0 (worst/non-diagnostic) and 4 (best).
Measured: up to 1.5 hours
Signal-to-Noise Ratio (SNR)
SNR will be evaluated for each DW-MRI dataset, using an expectation-maximization method, accounting for parallel imaging, spatially varying noise, and magnitude operation
Measured: up to 1.5 hours
Cross-correlation coefficient (CCC) of images
To assess image distortions in DW-MRI, the cross-correlation coefficient (CCC) will be used to assess alignment between each of the DW-MRI datasets and the reference T2-weighted acquisition.
Measured: up to 1.5 hours
Overall Image Quality Score
Each DW-MRI reconstruction will be evaluated by three radiologists using a Likert scale between 0 (worst/non-diagnostic) and 4 (best) for several criteria: motion artifacts, spatial resolution, distortions, apparent SNR, and overall image quality. The post-contrast images will serve as a guide to assess for artifacts by demonstrating the liver and the lesions.
Measured: up to 1.5 hours
Sensitivity: Number of True Positive Assessments divided by Number of All Positive Assessments
Per-lesion sensitivity will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.
Measured: up to 1.5 hours
Specificity: Number of True Negative Assessments divided by Number of All Negative Assessments
Per-lesion specificity will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.
Measured: up to 1.5 hours
Accuracy: Number of Correct Assessments divided by Number of All Assessments
Per-lesion accuracy will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.
Measured: up to 1.5 hours
Repeat ADC Measurements to Assess Intra-Reader Variability
Intra-reader variability will be assessed by each reader with repeating ADC measurements after two months
Measured: up to 1.5 hours
ACD Measures For Each Reader to assess Inter-Reader Variability
Inter-reader variability will be assessed in ADC measurements by comparing matching lesions, based on the recorded lesion location across readers.
Measured: up to 1.5 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2022
- Study start22 Nov 2023
- Primary completion30 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Abdominal ImagingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Biomedical Imaging and Bioengineering (NIBIB)
- Responsible party
- Sponsor
- Investigators
- Diego Hernando, PhD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05261633
- Sponsor's protocol ID
- 2021-1289
- Other IDs
- Protocol Version 10/17/2025, A539300, 1R01EB030497-01
- Status last verified
- Jun 2026
- First submitted
- 3 Feb 2022
- Last updated
- 2 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diffusion Magnetic Resonance Imaging (MRI) of the Abdomen
- ClinicalTrials.gov ID
- NCT05261633
- Acronym / sponsor ID
- 2021-1289
- Conditions
- Abdominal Imaging
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 17 participants (actual)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Collaborators
- National Institute for Biomedical Imaging and Bioengineering (NIBIB)
- Study start
- 22 Nov 2023 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 2 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research is to see if a new magnetic resonance imaging (MRI) method will be able to improve the images taken of the abdomen. This new method includes some changes to help avoid movements that may disrupt the images like breathing, heartbeats and other involuntary motion that occurs in the abdomen. This study will these methods in healthy volunteers and validate them in patients with known liver metastases in a single contrast-enhanced MRI visit.
Detailed description
This study will develop and validate novel DW-MRI methods with unprecedented robustness to motion, favorable image quality, and quantitative precision for abdominal imaging. Upon successful completion, these methods will have broad applications, including the assessment of cancer, fibrosis and other disease processes in various abdominal organs such as the liver, pancreas, kidneys, bowel and beyond.
The primary objective is to demonstrate precise quantitative diffusion parameter mapping that is achieved by the novel, motion-robust, low-distortion DW-MRI methods in a representative and clinically relevant application, for the assessment of liver metastatic disease. Specifically, the investigators will:
- Compare the repeatability of DW-MRI methods by calculating the squared difference between each pair of repeated ADC measurements in lesions and healthy tissue, and will model this value including the DW-MRI method as a covariate using Generalized Estimating Equations (GEE).
Secondary objectives include optimization of the methods in healthy volunteers, assessment of image quality and distortions, as well gathering preliminary data for assessment of sensitivity and specificity for detection of lesions:
- Optimization in healthy volunteers
- (Aim 1) Optimized bh, M1 and M2 parameters by minimization of the mean squared error and bias of ADC quantification across the liver
- (Aim 2) Optimized motion-corrected averaging via image quality assessment by three radiologists using a Likert scale.
- SNR (signal-to-noise ratio) will be evaluated for each DW-MRI dataset, using an expectation-maximization method, accounting for parallel imaging, spatially varying noise, and magnitude operation.
- To assess image distortions in DW-MRI, the cross-correlation coefficient (CCC) will be used to assess alignment between each of the DW-MRI datasets and the reference T2-weighted acquisition.
- Each DW-MRI reconstruction will be evaluated by three radiologists using a Likert scale between 0 (worst/non-diagnostic) and 4 (best) for several criteria: motion artifacts, spatial resolution, distortions, apparent SNR, and overall image quality. The post-contrast images will serve as a guide to assess for artifacts by demonstrating the liver and the lesions.
- Per-lesion sensitivity, specificity, and accuracy will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.
- Intra-reader variability will be assessed by each reader will repeating ADC measurements after two months.
- Inter-reader variability will be assessed in ADC measurements by comparing matching lesions, based on the recorded lesion location across readers.
Specific Aims Aim 1: Optimize a reliable, motion-robust DW-MRI of the abdomen in healthy volunteers.
Aim 2: Optimize, in healthy volunteers, a high-resolution, low-distortion, motion-robust DW-MRI of the abdomen through the synergistic combination of motion-robust DW-MRI with state-of-the-art low-distortion techniques.
Aim 3: Demonstrate excellent image quality and precise quantitative diffusion parameter mapping using the novel DW-MRI methods in a representative and clinically relevant application for the assessment of liver metastases, by evaluating in patients:
3a. Quantitative and subjective image quality metrics. 3b. Precision (test-retest repeatability) of ADC measurements in the liver (including healthy parenchyma and lesions) by novel vs. standard DW-MRI methods.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy Volunteers | – | Device: Diffusion Weighted Magnetic Resonance Imaging |
| Known Liver Metastases | – | Device: Diffusion Weighted Magnetic Resonance Imaging |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Healthy volunteers and people with known liver metastases that are 18 years or older.
Key inclusion criteria (5 listed)
- 18 years of age or older
- 18 years of age or older
- Patients with at least one of the following:
Key exclusion criteria (11 listed)
- Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
- Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
- Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
- Patients with known contraindication to GBCA such as severe kidney disease or previously documented GFR < 30 ml/min/1.73 m2
- Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diffusion Weighted Magnetic Resonance ImagingAlso: DW-MRIDiffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs. | Device | Healthy Volunteers, Known Liver Metastases |
Primary outcome
Squared difference between each pair of repeated ADC measurements
Time frame: up to 1.5 hours
Compare the repeatability of DW-MRI methods by calculating the squared difference between each pair of repeated apparent diffusion coefficient (ADC) measurements in lesions and healthy tissue, and will model this value including the DW-MRI method as a covariate using Generalized Estimating Equations (GEE).
10 secondary outcomes
Mean Squared Error of ADC in images from Healthy Volunteers
Time frame: up to 1.5 hours
Image Quality Score in images from Healthy Volunteers
Time frame: up to 1.5 hours
Signal-to-Noise Ratio (SNR)
Time frame: up to 1.5 hours
Cross-correlation coefficient (CCC) of images
Time frame: up to 1.5 hours
Overall Image Quality Score
Time frame: up to 1.5 hours
Sensitivity: Number of True Positive Assessments divided by Number of All Positive Assessments
Time frame: up to 1.5 hours
Specificity: Number of True Negative Assessments divided by Number of All Negative Assessments
Time frame: up to 1.5 hours
Accuracy: Number of Correct Assessments divided by Number of All Assessments
Time frame: up to 1.5 hours
Repeat ADC Measurements to Assess Intra-Reader Variability
Time frame: up to 1.5 hours
ACD Measures For Each Reader to assess Inter-Reader Variability
Time frame: up to 1.5 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Abdominal Imaging
RecruitingPhase 3
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm
Enrolling by invitationObservational study
Intelligent Accelerated MRI for Pediatric Abdominal Pain
Pediatric Abdominal Pain
Recruiting
Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques
Abdominal Aortic Aneurysm
Active, not recruiting
A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System
Head and Neck Cancer, Thoracic Cancer
Not yet recruitingObservational study
Global Reference Ranges - Mexico
Healthy Adult Participants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Diego Hernando, PhD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Abdominal Imaging, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Squared difference between each pair of repeated ADC measurements (time frame: up to 1.5 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.